Boston Scientific enrolls patients for new stent

Boston Scientific, based in Natick, MA, is enrolling patients now in a trial for a new kind of drug-eluding coronary stent it calls Synergy. What makes it different from previous versions is that it is coated with a biodegradable polymer and drug formulation that will reduce reclogging more quickly than other stents. Then, it will disappear harmlessly, leaving only the metal stent in the vessel. The trial is expected to enroll 291 patients in Europe, Australia and New Zealand. Synergy is an investigational device in the United States. Boston Scientific's previous-generation Promus stent was approved in Europe late last year. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.